Advertisement

Pediatric Cardiology

, Volume 38, Issue 1, pp 155–161 | Cite as

Safety of Enalapril in Infants Admitted to the Neonatal Intensive Care Unit

  • Lawrence C. Ku
  • Kanecia Zimmerman
  • Daniel K. Benjamin
  • Reese H. Clark
  • Christoph P. Hornik
  • P. Brian Smith
  • on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
Original Article

Abstract

Enalapril is used to treat hypertension and congestive heart failure in infants. However, enalapril is not labeled for neonates, and safety data in infants are sparse. To evaluate the safety of enalapril in young infants, we conducted a retrospective cohort study of infants who were exposed to enalapril in the first 120 days of life and were cared for in 348 neonatal intensive care units from 1997 to 2012. We determined the proportion of exposed infants who developed adverse events, including death, hypotension requiring pressors, hyperkalemia, and elevated serum creatinine. Using multivariable logistic regression, we examined risk factors for adverse events, including postnatal age at first exposure, exposure duration, gestational age group, small for gestational age status, race, sex, 5-min Apgar score, and inborn status. Of a cohort of 887,910 infants, 662 infants (0.07%) were exposed to enalapril. Among exposed infants, 142 infants (21%) suffered an adverse event. The most common adverse event was hyperkalemia (13%), followed by elevated serum creatinine (5%), hypotension (4%), and death (0.5%). Significant risk factors for adverse events included postnatal age <30 days at first exposure and longer exposure duration. This study is the largest to date examining the safety of enalapril in young term and preterm infants without significant structural cardiac disease.

Keywords

Enalapril Drug safety Infant pharmacology Pharmacoepidemiology 

Notes

Acknowledgements

The Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee

Daniel K. Benjamin Jr., MD, PhD, Katherine Y. Berezny, BSMT, MPH, Michael Cohen-Wolkowiez, MD, PhD, Duke Clinical Research Institute, Durham, NC; Gregory L. Kearns, PharmD, PhD, Arkansas Children’s Hospital, Little Rock, AR; Matthew M. Laughon, MD, MPH, University of North Carolina, Chapel Hill, NC; Ian M. Paul, MD, MSc, Penn State College of Medicine, Hershey, PA; Michael J. Smith, MD, MSCE, University of Louisville, Louisville, KY; John van den Anker, MD, PhD, George Washington University School of Medicine and Health, Washington, DC; Kelly Wade, MD, Children’s Hospital of Philadelphia, Philadelphia, PA.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development

David Siegel, MD, Perdita Taylor-Zapata, MD, Anne Zajicek, PharmD, Zhaoxia Ren, MD, PhD, Ekaterini Tsilou, MD, Alice Pagan, BBA.

The EMMES Corporation (Data Coordinating Center)

Ravinder Anand, PhD, Traci Clemons, PhD, Gina Simone, BS.

Funding

Dr. Ku receives research support from the National Institute of Child Health and Human Development (5T32GM086330-03, 5T32HD043029-13, and 4K12HD043494-14). Dr. Zimmerman receives research support from the Duke Clinical and Translational Science Awards (KL2TR001115-03). Dr. Hornik receives research support for research from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) (UL1TR001117). Dr. Smith receives salary support for research from the NIH and the National Center for Advancing Translational Sciences of the NIH (UL1TR001117), the National Institute of Child Health and Human Development (HHSN275201000003I and 1R01-HD081044-01) and the Food and Drug Administration (1R18-FD005292-01); he also receives research support from Cempra Pharmaceuticals (subaward to HHS0100201300009C) and industry for neonatal and pediatric drug development (www.dcri.duke.edu/research/coi.jsp). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Dr. Benjamin and Dr. Clark have nothing to disclose.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

For this type of study, formal consent is not required. Approval for this study was obtained from the Duke University Institutional Review Board.

References

  1. 1.
    Dutertre JP, Billaud EM, Autret E, Chantepie A, Oliver I, Laugier J (1993) Inhibition of angiotensin converting enzyme with enalapril maleate in infants with congestive heart failure. Br J Clin Pharmacol 35:528–530CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Frenneaux M, Stewart RA, Newman CM, Hallidie-Smith KA (1989) Enalapril for severe heart failure in infancy. Arch Dis Child 64:219–223CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Hanssens M, Keirse MJ, Vankelecom F, Van Assche FA (1991) Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol 78:128–135PubMedGoogle Scholar
  4. 4.
    Mason T, Polak M, Pyles L, Mullett M, Swanke C (1992) Treatment of neonatal renovascular hypertension with intravenous enalapril. Am J Perinatol 9:254–257CrossRefPubMedGoogle Scholar
  5. 5.
    BTA Pharmaceuticals, Inc. VASOTEC (enalapril maleate) tablet [updated June 2010]. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5d181743-a0fc-4d17-953d-b17a936f9ecc
  6. 6.
    Blowey DL, Duda PJ, Stokes P, Hall M (2011) Incidence and treatment of hypertension in the neonatal intensive care unit. J Am Soc Hypertens 5:478–483CrossRefPubMedGoogle Scholar
  7. 7.
    Dionne JM, Abitbol CL, Flynn JT (2012) Hypertension in infancy: diagnosis, management and outcome. Pediatr Nephrol 27:17–32CrossRefPubMedGoogle Scholar
  8. 8.
    Singh HP, Hurley RM, Myers TF (1992) Neonatal hypertension. Incidence and risk factors. Am J Hypertens 5:51–55PubMedGoogle Scholar
  9. 9.
    Hsu DT, Zak V, Mahony L, Sleeper LA, Atz AM, Levine JC et al (2010) Enalapril in infants with single ventricle results of a multicenter randomized trial. Circulation 122:333–340CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lindle KA, Dinh K, Moffett BS, Kyle WB, Montgomery NM, Denfield SD et al (2014) Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease. Pediatr Cardiol 35:499–506CrossRefPubMedGoogle Scholar
  11. 11.
    Bianchetti MG, Caflisch M, Oetliker OH (1992) Cough and converting enzyme inhibitors. Eur J Pediatr 151:225–226CrossRefPubMedGoogle Scholar
  12. 12.
    Delucchi A, Cano F, Rodriguez E, Wolff E, Gonzalez X, Cumsille MA (2000) Enalapril and prednisone in children with nephrotic-range proteinuria. Pediatr Nephrol 14:1088–1091CrossRefPubMedGoogle Scholar
  13. 13.
    Hom KA, Hirsch R, Elluru RG (2012) Antihypertensive drug-induced angioedema causing upper airway obstruction in children. Int J Pediatr Otorhinolaryngol 76:14–19CrossRefPubMedGoogle Scholar
  14. 14.
    Meyers RS, Siu A (2011) Pharmacotherapy review of chronic pediatric hypertension. Clin Ther 33:1331–1356CrossRefPubMedGoogle Scholar
  15. 15.
    Schaefer F, Litwin M, Zachwieja J, Zurowska A, Turi S, Grosso A et al (2011) Efficacy and safety of valsartan compared to enalapril in hypertensive children. J Hypertens 29:2484–2490CrossRefPubMedGoogle Scholar
  16. 16.
    Webb NJA, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP et al (2012) Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int 82:819–826CrossRefPubMedGoogle Scholar
  17. 17.
    Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P et al (2002) A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 42:870–880CrossRefPubMedGoogle Scholar
  18. 18.
    Testoni D, Hayashi M, Cohen-Wolkowiez M, Benjamin DK Jr, Lopes RD, Clark RH et al (2014) Late-onset bloodstream infections in hospitalized term infants. Pediatr Infect Dis J 33:920–923CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Linhart Y, Bashiri A, Maymon E, Shoham-Vardi I, Furman B, Vardi H et al (2000) Congenital anomalies are an independent risk factor for neonatal morbidity and perinatal mortality in preterm birth. Eur J Obstet Gynecol Reprod Biol 90:43–49CrossRefPubMedGoogle Scholar
  20. 20.
    Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS (2001) Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104:1985–1991CrossRefPubMedGoogle Scholar
  21. 21.
    Raebel MA (2012) Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 30:e156–e166CrossRefPubMedGoogle Scholar
  22. 22.
    Fanos V, Dessi A, Puddu M, Ottonello G (2014) Perinatal asphyxia and kidney development. In: Faa G, Fanos V (eds) Kidney development in renal pathology. Springer, New York, pp 59–66Google Scholar
  23. 23.
    Lorenz JM, Kleinman LI, Ahmed G, Markarian K (1995) Phases of fluid and electrolyte homeostasis in the extremely low birth weight infant. Pediatrics 96:484–489PubMedGoogle Scholar
  24. 24.
    Nakamura H, Ishii M, Sugimura T, Chiba K, Kato H, Ishizaki T (1994) The kinetic profiles of enalapril and enalaprilat and their possible developmental changes in pediatric patients with congestive heart failure. Clin Pharm Ther 56:160–168CrossRefGoogle Scholar
  25. 25.
    Guron G, Friberg P (2000) An intact renin-angiotensin system is a prerequisite for normal renal development. J Hypertens 18:123–137CrossRefPubMedGoogle Scholar
  26. 26.
    Ku LC, Smith PB (2015) Dosing in neonates: special considerations in physiology and trial design. Pediatr Res 77:2–9CrossRefPubMedGoogle Scholar
  27. 27.
    Filler G, Wong H, Condello AS, Charbonneau C, Sinclair B, Kovesi T et al (2003) Early dialysis in a neonate with intrauterine lisinopril exposure. Arch Dis Child Fetal Neonatal Ed 88:F154–F156CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Murki S, Kumar P, Dutta S, Narang A (2005) Fatal neonatal renal failure due to maternal enalapril ingestion. J Matern Fetal Neonatal Med 17:235–237CrossRefPubMedGoogle Scholar
  29. 29.
    Schubiger G, Flury G, Nussberger J (1988) Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. Ann Intern Med 108:215–216CrossRefPubMedGoogle Scholar
  30. 30.
    Ratnapalan S, Koren G (2002) Taking ACE inhibitors during pregnancy. Is it safe? Can Fam Physician 48:1047–1049PubMedPubMedCentralGoogle Scholar
  31. 31.
    Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA (2003) Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Pharmacoepidemiol Drug Saf 12:633–646CrossRefPubMedGoogle Scholar
  32. 32.
    Guron G, Molne J, Swerkersson S, Friberg P, Hansson S (2006) A 14-year-old girl with renal abnormalities after brief intrauterine exposure to enalapril during late gestation. Nephrol Dial Transplant 21:522–525CrossRefPubMedGoogle Scholar
  33. 33.
    Schilder J, Van den Anker J (1995) Use of enalapril in neonatal hypertension. Acta Paediatr 84:1426–1428CrossRefPubMedGoogle Scholar
  34. 34.
    Wells TG, Bunchman TE, Kearns GL (1990) Treatment of neonatal hypertension with enalaprilat. J Pediatr 117:664–667CrossRefPubMedGoogle Scholar
  35. 35.
    Dutta S, Narang A (2003) Enalapril-induced acute renal failure in a newborn infant. Pediatr Nephrol 18:570–572PubMedGoogle Scholar
  36. 36.
    Russo A, Mirani A, Perlman J, Miller S (2013) Enalapril-induced acute kidney injury in neonates. J Neonatal Perinatal Med 6:179–181PubMedGoogle Scholar
  37. 37.
    Zimmerman KO, Hornik CP, Ku L, Watt K, Laughon MM, Bidegain M et al (2015) Sedatives and analgesics given to infants in neonatal intensive care units at the end of life. J Pediatr 167:299e3–304e3CrossRefGoogle Scholar
  38. 38.
    Laughon MM, Chantala K, Aliaga S, Herring AH, Hornik CP, Hughes R et al (2015) Diuretic exposure in premature infants from 1997 to 2011. Am J Perinatol 32:49–56PubMedGoogle Scholar
  39. 39.
    Testoni D, Hornik CP, Neely ML, Yang Q, McMahon AW, Clark RH et al (2015) Safety of octreotide in hospitalized infants. Early Hum Dev 91:387–392CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Chu PY, Hill KD, Clark RH, Smith PB, Hornik CP (2015) Treatment of supraventricular tachycardia in infants: analysis of a large multicenter database. Early Hum Dev 91:345–350CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin DK Jr, Smith PB et al (2014) Medication use in the neonatal intensive care unit. Am J Perinatol 31:811–821CrossRefPubMedGoogle Scholar
  42. 42.
    Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB Jr, Kohn RM et al (1996) Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 131:350–355CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Lawrence C. Ku
    • 1
    • 2
  • Kanecia Zimmerman
    • 1
    • 2
  • Daniel K. Benjamin
    • 3
  • Reese H. Clark
    • 4
  • Christoph P. Hornik
    • 1
    • 2
  • P. Brian Smith
    • 1
    • 2
  • on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee
  1. 1.Department of PediatricsDuke University School of MedicineDurhamUSA
  2. 2.Duke Clinical Research InstituteDuke University School of MedicineDurhamUSA
  3. 3.Clemson UniversityClemsonUSA
  4. 4.Pediatrix-Obstetrix Center for Research and EducationSunriseUSA

Personalised recommendations